 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Benitec Raises Funds for HCV Trial through Private Placement
March 07, 2013
Benitec Raises Funds for HCV Trial through Private Placement
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Benitec Provides Pipeline Update Following Tacere Acquisition
October 18, 2012 / Gene Silencing News - Benitec Reacquires HCV Program in Tacere Therapeutics Buyout
October 11, 2012 / Gene Silencing News - Benitec Reveals Delays in its Pipeline Programs as Corporate Revitalization Continues
June 21, 2012 / Gene Silencing News - Benitec Aims for Three Clinical Programs, Industry Partnership in 2013
April 5, 2012 / Gene Silencing News - Benitec, Biomics Advance HBV Partnership
February 24, 2011 / Gene Silencing News